DK0968291T3 - Antistoffragment-polymerkonjugater - Google Patents
Antistoffragment-polymerkonjugaterInfo
- Publication number
- DK0968291T3 DK0968291T3 DK98911392T DK98911392T DK0968291T3 DK 0968291 T3 DK0968291 T3 DK 0968291T3 DK 98911392 T DK98911392 T DK 98911392T DK 98911392 T DK98911392 T DK 98911392T DK 0968291 T3 DK0968291 T3 DK 0968291T3
- Authority
- DK
- Denmark
- Prior art keywords
- conjugate
- polypeptide
- nppms
- nucleic acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/804,444 US6117980A (en) | 1997-02-21 | 1997-02-21 | Humanized anti-IL-8 monoclonal antibodies |
| US1211698A | 1998-01-22 | 1998-01-22 | |
| PCT/US1998/003337 WO1998037200A2 (en) | 1997-02-21 | 1998-02-20 | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0968291T3 true DK0968291T3 (da) | 2004-06-07 |
Family
ID=26683183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98911392T DK0968291T3 (da) | 1997-02-21 | 1998-02-20 | Antistoffragment-polymerkonjugater |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6870033B1 (da) |
| EP (2) | EP1415998A3 (da) |
| JP (1) | JP4108760B2 (da) |
| CN (1) | CN1297480A (da) |
| AT (1) | ATE258599T1 (da) |
| AU (1) | AU746819B2 (da) |
| BR (2) | BRPI9807464B1 (da) |
| CA (2) | CA2615918C (da) |
| DE (1) | DE69821338T2 (da) |
| DK (1) | DK0968291T3 (da) |
| ES (1) | ES2215295T3 (da) |
| IL (2) | IL131406A0 (da) |
| NZ (2) | NZ336839A (da) |
| PT (1) | PT968291E (da) |
| WO (1) | WO1998037200A2 (da) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| NZ336839A (en) | 1997-02-21 | 2001-08-31 | Genentech Inc | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| AU7266698A (en) | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| CN1269805A (zh) | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
| US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
| JP2002534119A (ja) * | 1999-01-14 | 2002-10-15 | ボルダー バイオテクノロジー， インコーポレイテッド | 自由システイン残基を有するタンパク質の生産方法 |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| DK1283214T3 (da) | 2000-04-21 | 2007-06-11 | Fuso Pharmaceutical Ind | Hidtil ukendte kollektiner |
| US7521047B2 (en) | 2000-05-12 | 2009-04-21 | Gpc Biotech Ag | Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| ITMI20010347A1 (it) | 2001-02-21 | 2002-08-21 | Grisotech S A | Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale |
| GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP1874820A4 (en) * | 2005-04-20 | 2010-09-22 | Amgen Fremont Inc | HIGH AFFINE, COMPLETELY HUMAN MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES |
| US8529897B2 (en) | 2007-08-16 | 2013-09-10 | Carnegie Mellon University | Inflammation-regulating compositions and methods |
| US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| CN101348526B (zh) * | 2008-08-29 | 2011-08-17 | 浙江大学 | 一种抗白细胞介素-8抗体 |
| US8030026B2 (en) * | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
| ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB0920324D0 (en) * | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
| US8309299B2 (en) * | 2010-05-19 | 2012-11-13 | Hoffmann-La Roche Inc. | Combination therapy and method for assessing resistance to treatment |
| US9023791B2 (en) * | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| US9803004B2 (en) | 2011-11-11 | 2017-10-31 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| CN105378099B (zh) | 2013-03-14 | 2021-05-11 | 雅培制药有限公司 | Hcv核心脂质结合结构域单克隆抗体 |
| EP2970947A4 (en) | 2013-03-14 | 2016-10-12 | Abbott Lab | RECOMBINANT HCV NS3 ANTIGENS AND THEIR MUTANTS FOR ENHANCED ANTIBODY DETECTION |
| JP6505076B2 (ja) | 2013-03-14 | 2019-04-24 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物 |
| EP2829608A1 (en) | 2013-07-23 | 2015-01-28 | Universität Bielefeld | Method for recombinant protein production in mammalian cells |
| PE20160674A1 (es) * | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3789039A1 (en) * | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2019089472A1 (en) * | 2017-11-01 | 2019-05-09 | Nantbio, Inc. | Il8 blocking emt pathway and overcoming cancer stem cells |
| MX2020006171A (es) | 2018-01-12 | 2020-09-03 | Bristol Myers Squibb Co | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| KR20230117588A (ko) | 2020-12-07 | 2023-08-08 | 유씨비 바이오파마 에스알엘 | 다중특이적 항체 및 항체 조합 |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| CN116003616B (zh) * | 2023-02-07 | 2026-03-24 | 杭州旭科生物技术有限公司 | 一种抗甲苯噻嗪单克隆抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4732863A (en) | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| JP2761881B2 (ja) | 1988-03-10 | 1998-06-04 | チッソ株式会社 | 抗体を固定化したアフイニテイクロマトグラフイ用担体 |
| US5652338A (en) | 1988-03-16 | 1997-07-29 | The United States Of America As Represented By The Department Of Health And Human Services | Neutrophil chemotactic factor |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| US5620689A (en) | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| IE913192A1 (en) | 1990-09-12 | 1992-02-25 | Scripps Research Inst | Active site of interleukin-8: polypeptide analogs and¹antibodies |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5169627A (en) | 1991-10-28 | 1992-12-08 | Mount Sinai School Of Medicine Of The City University Of New York | Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity |
| CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
| EP0679095A1 (en) | 1992-11-25 | 1995-11-02 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| EP0730660A4 (en) | 1993-10-29 | 1998-02-25 | Incyte Pharma Inc | CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS |
| US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US5702946A (en) | 1994-03-03 | 1997-12-30 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders |
| US5874080A (en) * | 1994-03-03 | 1999-02-23 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of asthma |
| CA2183550A1 (en) | 1994-03-04 | 1995-09-08 | Craig M. Lewis | In vitro antibody affinity maturation using alanine scanning mutagenesis |
| WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| AU4771696A (en) | 1995-01-23 | 1996-08-14 | Regents Of The University Of California, The | Methods for the treatment of acid aspiration-induced acute lung injury |
| US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| US6359114B1 (en) | 1995-06-07 | 2002-03-19 | Aphton Corp. | System for method for the modification and purification of proteins |
| KR19990063648A (ko) | 1995-09-21 | 1999-07-26 | 프레드한 아룬디프 에스 | 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법 |
| US5679532A (en) | 1995-12-13 | 1997-10-21 | University Technology Corporation | Serum ferritin as a predictor of the acute respiratory distress syndrome |
| WO1997040215A1 (fr) | 1996-04-23 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Medicament contre l'infarctus du myocarde contenant comme principe actif un anticorps anti-il-8 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| NZ336839A (en) | 1997-02-21 | 2001-08-31 | Genentech Inc | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| WO1999037779A1 (en) | 1998-01-22 | 1999-07-29 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
-
1998
- 1998-02-20 NZ NZ336839A patent/NZ336839A/en unknown
- 1998-02-20 PT PT98911392T patent/PT968291E/pt unknown
- 1998-02-20 ES ES98911392T patent/ES2215295T3/es not_active Expired - Lifetime
- 1998-02-20 JP JP53690598A patent/JP4108760B2/ja not_active Expired - Lifetime
- 1998-02-20 BR BRPI9807464-4A patent/BRPI9807464B1/pt unknown
- 1998-02-20 EP EP03019832A patent/EP1415998A3/en not_active Withdrawn
- 1998-02-20 IL IL13140698A patent/IL131406A0/xx active IP Right Grant
- 1998-02-20 CA CA2615918A patent/CA2615918C/en not_active Expired - Lifetime
- 1998-02-20 WO PCT/US1998/003337 patent/WO1998037200A2/en not_active Ceased
- 1998-02-20 DK DK98911392T patent/DK0968291T3/da active
- 1998-02-20 CN CN98802735A patent/CN1297480A/zh active Pending
- 1998-02-20 CA CA002281794A patent/CA2281794A1/en not_active Abandoned
- 1998-02-20 NZ NZ511956A patent/NZ511956A/xx not_active IP Right Cessation
- 1998-02-20 AT AT98911392T patent/ATE258599T1/de active
- 1998-02-20 AU AU65357/98A patent/AU746819B2/en not_active Expired
- 1998-02-20 EP EP98911392A patent/EP0968291B1/en not_active Expired - Lifetime
- 1998-02-20 US US09/355,014 patent/US6870033B1/en not_active Expired - Fee Related
- 1998-02-20 BR BR9807464-4A patent/BR9807464A/pt not_active IP Right Cessation
- 1998-02-20 DE DE69821338T patent/DE69821338T2/de not_active Expired - Lifetime
-
1999
- 1999-08-15 IL IL131406A patent/IL131406A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1297480A (zh) | 2001-05-30 |
| AU6535798A (en) | 1998-09-09 |
| BR9807464A (pt) | 2000-05-09 |
| EP0968291A2 (en) | 2000-01-05 |
| EP1415998A2 (en) | 2004-05-06 |
| PT968291E (pt) | 2004-06-30 |
| EP1415998A3 (en) | 2005-11-23 |
| EP0968291B1 (en) | 2004-01-28 |
| DE69821338D1 (de) | 2004-03-04 |
| US6870033B1 (en) | 2005-03-22 |
| NZ511956A (en) | 2002-11-26 |
| ATE258599T1 (de) | 2004-02-15 |
| AU746819B2 (en) | 2002-05-02 |
| CA2615918C (en) | 2013-11-26 |
| JP4108760B2 (ja) | 2008-06-25 |
| JP2001512489A (ja) | 2001-08-21 |
| CA2281794A1 (en) | 1998-08-27 |
| IL131406A0 (en) | 2001-01-28 |
| BRPI9807464B1 (pt) | 2017-11-21 |
| DE69821338T2 (de) | 2004-10-21 |
| IL131406A (en) | 2007-03-08 |
| WO1998037200A2 (en) | 1998-08-27 |
| CA2615918A1 (en) | 1998-08-27 |
| NZ336839A (en) | 2001-08-31 |
| WO1998037200A3 (en) | 1999-01-28 |
| ES2215295T3 (es) | 2004-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE258599T1 (de) | Antikörperfragment-polymerkonjugate | |
| DE69412614D1 (de) | Recombinante disulfid-stabilisierte polypeptide mit bindung spezifität | |
| CY1107708T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης | |
| WO2004016769A3 (en) | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof | |
| CY1121451T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4 | |
| DE69840669D1 (de) | Pca3, pca3-gene und verfahren zu ihrer verwendung | |
| ATE440868T1 (de) | Monoklonaler antikírper gegen ein prion protein und dessen verwendung zum nachweis von prionen | |
| DK19290D0 (da) | Molekulaer samling af antistofgener, antistoffer fremstillet derved samt anvendelse deraf | |
| WO2004050683A8 (en) | Antibodies directed to tumor necrosis factor and uses thereof | |
| DK1413584T3 (da) | Fotoprotein med forbedret bioluminescens | |
| DE68928532D1 (de) | Funktionelles, durch ein rekombinantes verfahren hergestelltes synthetisches proteinpolymer | |
| BRPI0511782B8 (pt) | anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor | |
| BR9507594B8 (pt) | Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante. | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| WO2000024884A3 (en) | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility | |
| WO2003057857A3 (en) | Antibodies directed to pdgfd and uses thereof | |
| DE69029808D1 (de) | Monoklonale antikörper | |
| BR9809778A (pt) | Polinucleotìdeo isolado, vetor de expressão, peptìdeo ou polipetìdeo isolado, anticorpo, processo para produzir o mesmo, fragmentos de anticorpos, anticorpos de cadeia única ou anticorpos humanizados, e, anticorpo anti-idiotìpico. | |
| WO2002018443A3 (en) | A recombinant monoclonal antibody to phosphotyrosine-containing proteins | |
| BR9811421A (pt) | Biomolécula, molécula de ácido nucleico, vetor, e uso de uma biomolécula | |
| Diez-Caballero et al. | Controlled Photoiniferter RAFT-Based Development of Linear Polymers Induced by the Presence of a Peptide to Produce Synthetic Antibody Substitutes Applicable to Immunofluorescence Imaging Techniques | |
| HUP9902713A2 (hu) | Ráksejteket specifikusan detektáló antigénkötő fragmensek, a fragmenseket kódoló nukleotidok és alkalmazásuk rák megelőzésére, és kimutatására | |
| CY1117395T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων |